In this episode of Expose MASH [formerly NASH]—intended for US healthcare professionals only—we will share insights on the current MASH guidelines. The adoption of the new MASH nomenclature, with the inclusion of cardiometabolic risk factors into its formal definition, will be briefly discussed before examining the different clinical guidelines that are available. We will identify shared recommendations and key points of difference for the screening and management of this complex disease. We will then look to the future to discuss how emerging data may inform future guidelines and help optimize clinical practice. This episode is brought to you by Novo Nordisk Inc.
On this episode, join experts Mazen Noureddin, MD, MHS (Transplant Hepatologist and Professor of Medicine at Houston Methodist Hospital), Rita Basu, MD (Endocrinologist and Endowed Professor of Diabetes Scienceat University of Alabama at Birmingham) and Mary Rinella, MD (Transplant Hepatologist and Professor of Medicine at The University of Chicago Medicine), as they explore the most recent MASH guidelines. The experts discuss the different guidelines available, examining their common features and subtle differences for patient screening and the management of MASLD and MASH. They then look to the future, highlighting the emerging data that may influence the next iterations of these guidance documents and inform clinical practice.
This program is intended for clinicians in the US only. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk Inc. This podcast is not to be used as medical advice and is intended for educational purposes only.
Faculty Presenters:
Mazen Noureddin, MD, MHS
Transplant Hepatologist and Professor of Medicine
Houston Methodist Hospital
Houston, TX
Rita Basu, MD
Endocrinologist and Endowed Professor of Diabetes Science
University of Alabama at Birmingham
Birmingham, AL
Mary Rinella, MD
Transplant Hepatologist and Professor of Medicine
The University of Chicago Medicine
Chicago, IL
Click here for full reference list
References
Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138-1153.
American Diabetes Association Professional Practice Committee. 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of care in diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S49-S67.
American Diabetes Association Professional Practice Committee. 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of care in diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S52-S76.
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357.
Cusi K, Budd J, Johnson E, Shubrook J. Making sense of the nonalcoholic fatty liver disease clinical practice guidelines: what clinicians need to know. Diabetes Spectr. 2024;37(1):29-38.
Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings. Endocr Pract. 2022;28(5):528-562.
Dalal N, Catalli L, Miller SA, et al. BRIDGE to liver health: implementation of a group telehealth psychoeducational program through shared medical appointments for MASLD management. BMC Public Health. 2024;24(1):1546.
Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123-133.
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;S0168-8278(24)00329-5. doi: 10.1016/j.jhep.2024.04.031.
Kanwal F, Shubrook JH, Adams LA, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology. 2021;161(5):1657-1669.
Kanwal F, Shubrook JH, Younossi Z, et al. Preparing for the NASH epidemic: a call to action. Obesity (Silver Spring). 2021;29:1401-1412.
Nadolsky K, Cryer DR, Articolo A, Fisher T, Schneider J, Rinella M. Nonalcoholic steatohepatitis diagnosis and treatment from the perspective of patients and primary care physicians: a cross-sectional survey. Ann Med. 2023;55(1):2211349.
Rezdiffra™ [package insert]. West Conshohocken, PA:Madrigal Pharmaceuticals; 2024.
Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542-1556.
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835.
Schattenberg JM, Lazarus JV, Newsome PN, et al. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: a cost-of-illness analysis. Liver Int. 2021;41(6):1227-1242.
Stefano JT, Duarte SMB, Ribeiro Leite Altikes RG, Oliveira CP. Non-pharmacological management options for MAFLD: a practical guide.Ther Adv Endocrinol Metab. 2023;14:20420188231160394.
Tamaki N, Ahlholm N, Luukkonen PK, et al. Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease. J Clin Invest. 2022;132(21):e162513.
Wada T, Zeniya M. Background of the FIB-4 index in Japanese non-alcoholic fatty liver disease. Intern Med. 2015;54(2):127-32.
Wattacheril JJ, Abdelmalek MF, Lim JK, Sanyal AJ. AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review. Gastroenterology. 2023;165(4):1080-1088.
Woodard JS, Abrams GA. Increased prevalence of advanced metabolic dysfunction-associated steatotic liver disease fibrosis in Type 2 diabetics despite low-risk Fibrosis-4 index scores. J Endocrinol Metab. 2024;14(1):40-47.